NVO) “might have an edge” over rival Eli Lilly (NYSE...Kumar now sees NVO shares as more attractive than Eli Lilly primarily because, efficacy-wise, the oral Wegovy “looks better” than its US rival’s product – at least on the basis of clinical trials.
Eli Lilly has asked the Food and Drug Administration to approve orforglipron after completing a Phase 3 trial showing it helped people maintain weight loss after stopping injectable drugs such as Wegovy and Zepbound.
ELI LILLY & Co [LLY] 5 ... LILLY CORPORATE CENTER 3 ... LILLY CORPORATE CENTER ... Eli Lilly and Company published this content on December 16, 2025, and is solely responsible for the information contained herein.
Shares of global pharmaceutical company Eli Lilly (NYSE... Is now the time to buy Eli Lilly? Access our full analysis report here.What Is The Market Telling Us. Eli Lilly’s shares are somewhat volatile ...
The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill ... .